To include your compound in the COVID-19 Resource Center, submit it here.

Market recalibrates Biogen’s valuation as aducanumab filing is delayed

Roller-coaster ride for Alzheimer’s therapy continues as investors reassess its chances for success submission.

Biogen’s aducanumab roller-coaster ride continued Wednesday as investors reassessed the risk for the Alzheimer’s therapy following a roughly six-month delay for the company’s BLA submission.

Biogen Inc. (NASDAQ:BIIB) disclosed Wednesday plans to push back an FDA submission date for aducanumab from early this year to 3Q20, triggering a $5.4 billion loss in market cap. The stock fell $31 to $298.01 on the day.

Biogen’s shares are now 37% below their five-year peak of $475.98; it crested on March 20, 2015 after announcing positive interim Phase Ib data for aducanumab.

Read the full 897 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers